Business Wire

MAVENIR

30.9.2021 15:02:04 CEST | Business Wire | Press release

Share
Mavenir Enables Intelligent Network Operations with Next-Generation OSS

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced its next-generation Operations Support System (ngOSS) , a new addition to the MAVscale platform.

The new solution brings together a powerful combination of Artificial Intelligence (AI), Analytics, Automation, and Orchestration, backed by Mavenir’s experience delivering telecom network solutions to allow Communication Service Providers (CSPs) to deploy ngOSS in their 4G networks today, while at the same time preparing to fully realize the potential of 5G capabilities through intelligent network operations.

By enhancing network performance, Mavenir’s ngOSS enables CSPs to improve the overall customer experience, lower operating expenses (OPEX), and reduce the risk of manual errors more prevalent in legacy OSS systems.

The end-to-end, cloud-native automation framework is built based on TM Forum’s Open Digital Architecture (ODA) and OpenAPIs that uses enhanced AI and Machine Learning (ML) models to deliver advanced network performance. Engineered with a microservices-based architecture, Mavenir's ngOSS solution simplifies large, legacy, monolithic systems into smaller, autonomous components that offer intelligence, insights, and network control. A more open, automated network is necessary to break legacy vendor lock-in while driving innovation for 5G use cases.

Mavenir is an OSS vendor with 4G/5G and mobile core/Radio Access Network (RAN) expertise, and in-depth understanding of orchestrating telecommunications workloads required for enabling advanced 5G capabilities, including network slicing, which translates directly into efficiencies for the CSPs.

“As CSPs advance toward automation, next-generation OSS will be a critical component to enable the network of the future,” said Kuntal Chowdhury, SVP and GM of AI and Analytics at Mavenir. “Using advanced AI and ML models to enhance network performance will help CSPs deliver superior customer experience, while scalable automation reduces manual tasks to lower maintenance costs and reduces the risk of human error. Mavenir’s ngOSS solution allows CSPs to break open the network and take advantage of Open APIs to increase agility and innovation, introduce new services, and monetize 5G with rapid service velocity.”

Key capabilities of Mavenir’s ngOSS include:

  • Service Fulfillment and Orchestration – Service Order Management integrates with the Business Support System (BSS) layer using Open APIs to deliver dynamic order creation, support complex workflow creation, and offer complete visibility & management into service order execution. Service Orchestration provides a complete network automation solution, including Service Design, 5G Slice Management, and Network Service Orchestration.
  • Data Management – Mavenir’s Provisioning and Activation function is radically different from the traditional provisioning offerings from legacy vendors. It elevates provisioning to a whole new level by offering Provisioning-as-a-Service on any cloud, from any vendor, on any domain approach. In addition, Mavenir’s Active Inventory collects, maintains, and exposes a federated real-time view of available network resources and services from across multiple cloud and vendor environments.
  • Service Assurance and AI Operations (AIOps) – Mavenir Service Assurance and AIOps platform addresses CSP’s operational challenges by providing end-to-end visibility into the network, enabling an open network by integrating with any cloud, any vendor, and any technology domain, and performing critical AIOps functions, such as AI-driven predictive alarm correlation, ML-assisted Ticket Analysis, and auto Root Cause Analysis (RCA), resulting in increased productivity, shorter Mean Time To Repair (MTTR), and OPEX savings.
  • Domain Controllers – Mavenir’s Non-Real-Time RAN Intelligent Controller (RIC) is a containerized application that uses advanced machine learning algorithms to optimize RAN performance and train ML models using long term RAN data for dynamic and adaptive policy and control. Mavenir’s Network Subnet Slice Management Function (NSSMF) is an open, cloud-native, and vendor-agnostic function that plays a crucial role in 5G slice management as it does the last-mile connections necessary to configure a slice.

Supporting documents:

Mavenir ngOSS webpage
Mavenir ngOSS solution brief

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye